Medicine and Dentistry
Lung Cancer
95%
Non Small Cell Lung Cancer
83%
Neoplasm
54%
Immune Checkpoint Inhibitor
40%
Immunotherapy
34%
Epidermal Growth Factor Receptor
32%
Non-Small Cell Lung Cancer
29%
Circulating Tumor DNA
27%
Oncology
26%
Immune-Related Adverse Events
23%
Immune Checkpoint Blockade
22%
Malignant Neoplasm
20%
Overall Survival
19%
Pneumonia
17%
Biological Marker
17%
Tyrosine-Kinase Inhibitor
17%
Targeted Therapy
16%
T Cell
16%
Progression Free Survival
16%
Brain Metastasis
15%
Radiation Therapy
15%
Exon
13%
Chemoradiotherapy
12%
Glycon
11%
Clinical Feature
11%
Margetuximab
11%
Quality Improvement
11%
Nivolumab
11%
Disease
9%
Arm
9%
Electronic Patient Record
9%
Immune Response
9%
DNA Determination
8%
Treatment of Non-Small Cell Lung Cancer
7%
Recurrent Disease
7%
Bevacizumab
7%
Durvalumab
7%
Disease Exacerbation
7%
Programmed Death 1 Ligand 1
6%
Gastroesophageal Junction
6%
Lymphocytopenia
6%
Counseling
6%
CD8 Antigen
6%
Osimertinib
6%
Adenocarcinoma
6%
Surgery
5%
Programmed Death-Ligand 1
5%
Monotherapy
5%
Acute Kidney Injury
5%
Gamma Urogastrone
5%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Immune Checkpoint Inhibitors
56%
Lung Cancer
36%
Immune Checkpoint Blockade
33%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
32%
Immune-related Adverse Events
29%
Clinical Outcomes
28%
Tumor
27%
Circulating Tumor DNA (ctDNA)
27%
Clinical Features
25%
Checkpoint Inhibitor Pneumonitis
22%
Targeted Therapy
18%
Immune Checkpoint
16%
IrAE
16%
Overall Survival
14%
Programmed Death-ligand 1 (PD-L1)
14%
Neoadjuvant
14%
EGFR mutation
13%
Brain Metastases
12%
Cancer Immunotherapy
12%
Neoantigen
12%
Oncology
12%
Immune Response
11%
Margetuximab
11%
Survivors
11%
Epigenetic Therapy
11%
Metformin
11%
Definitive Chemoradiation
11%
Gastroesophageal Junction Cancer
11%
Epidermal Growth Factor Receptor
11%
Anti-PD-1
10%
Clinical Trials
9%
Pathological Response
9%
DNA Analysis
8%
T Cells
8%
Platinum-based Chemotherapy
8%
Tumor-immune System
8%
Chemotherapy
8%
Tumor Immunity
8%
Tumor Response
8%
Patient Survival
7%
Clinical Response
7%
Bevacizumab
7%
Small Cell Lung Cancer
7%
Immune Toxicity
7%
Metastatic Non-small Cell Lung Cancer
7%
Progression-free Survival
7%
Patients with Cancer
6%
Confidence Interval
6%
Nivolumab
6%